Citizens JMP Reiterates Market Outperform Rating on Aura Biosciences (AURA)

Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Aura Biosciences (NASDAQ: AURA).

The analyst commented, “1Q25 OpEx of $29M was above consensus estimates of $24M, but in line with our estimates of $29. For the quarter, AURA had a net loss of $29M, or ($0.55) per share, vs. the consensus of ($0.44). The company ended the quarter with $199M in proforma cash. AURA had previously guided to cash runway into 2H26 with management telling us the financing provides 6-9 months of additional runway. We update our model for AURA’s financial results, financing, 10- Q filing and roll forward the discount period in our DCF analysis. We lower our discount rate to 11% (from 12.5%) due removing the cash overhang, which we expect will allow for greater upside potential on positive data in choroidal metastases and NMIBC later this year.”

For an analyst ratings summary and ratings history on Aura Biosciences click here. For more ratings news on Aura Biosciences click here.

Shares of Aura Biosciences closed at $5.95 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'